NewAmsterdam Pharma Co N.V. (NAMS): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$220.0K

Year ended 2025-12-31

$244.0K

Trailing 12 months to 2026-06-30

+190.2%

3-year compound annual growth

2021-12-31 Depreciation & Amortization (USD) 2025-12-31

Period ended	Depreciation & Amortization	Change YoY	Source filing
2025-12-31	$220.0K	+94.7%	2026-02-18, From 2025-01-01
2024-12-31	$113.0K	+130.6%	2026-02-18, From 2024-01-01
2023-12-31	$49.0K	+444.4%	2026-02-18, From 2023-01-01
2022-12-31	$9.0K	+80.0%	2025-02-26, From 2022-01-01
2021-12-31	$5.0K	n/a	2024-02-28, From 2021-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Depreciation & Amortization	Change YoY
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	$220.0K	+94.7%
Alumis Inc. (ALMS)	2025-12-31	$3.50M	+10.9%
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	$1.20M	-7.7%
Scynexis Inc (SCYX)	2024-12-31	$0	-100.0%
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	$109.0K	-53.2%
Celularity Inc (CELU)	2025-12-31	$7.29M	-7.9%
Cue Biopharma, Inc. (CUE)	2025-12-31	$958.0K	+141.3%
Foghorn Therapeutics Inc. (FHTX)	2025-12-31	$3.33M	+6.8%
uniQure N.V. (QURE)	2025-12-31	$14.76M	+16.8%

Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗